-
Three Russia-themed anti-war films shortlisted for Oscars
-
US oil blockade of Venezuela: what we know
-
Palace boss Glasner says contract talks on hold due to hectic schedule
-
Netflix to launch FIFA World Cup video game
-
Venezuela says oil exports continue normally despite Trump 'blockade'
-
German MPs approve 50 bn euros in military purchases
-
India v South Africa 4th T20 abandoned due to fog
-
Hydrogen plays part in global warming: study
-
EU's Mercosur trade deal hits French, Italian roadblock
-
What next for Belarus after US deal on prisoners, sanctions?
-
Brazil Senate debates bill that could slash Bolsonaro jail term
-
Coe shares 'frustration' over marathon record despite Kenyan's doping ban
-
Stolen Bruce Lee statue 'returns' to Bosnia town
-
Veteran Suarez signs new Inter Miami contract
-
Warner Bros rejects Paramount bid, sticks with Netflix
-
Crude prices surge after Trump orders Venezuela oil blockade
-
Balkan nations offer lessons on handling cow virus sowing turmoil
-
French readers lap up Sarkozy's prison diaries
-
UK PM warns Abramovich 'clock is ticking' over Chelsea sale fund
-
Warner Bros. Discovery rejects Paramount bid
-
Winners of 2026 World Cup to pocket $50 million in prize money
-
World no. 1 Alcaraz ends 'incredible ride' with coach Ferrero
-
World number one Alcaraz announces 'difficult' split with coach Ferrero
-
Iran boxer sentenced to death at 'imminent' risk of execution: rights groups
-
Snicko operator admits error that led to Carey's Ashes reprieve
-
Finland PM apologises to Asian countries over MPs' mocking posts
-
Doctors in England go on strike for 14th time
-
Romania journalists back media outlet that sparked graft protests
-
Rob Reiner's son awaiting court appearance on murder charges
-
Ghana's Highlife finds its rhythm on UNESCO world stage
-
Stocks gain as traders bet on interest rate moves
-
France probes 'foreign interference' after malware found on ferry
-
Europe's Ariane 6 rocket puts EU navigation satellites in orbit
-
Bleak end to the year as German business morale drops
-
Hundreds queue at Louvre museum as strike vote delays opening
-
Bondi shooting shocks, angers Australia's Jewish community
-
Markets rise even as US jobs data fail to boost rate cut bets
-
Senegal talisman Mane overcame grief to become an African icon
-
Carey pays tribute to late father after home Ashes century
-
'Many lessons to be learned' from Winter Games preparations, says ski chief
-
Emotional Carey slams ton to give Australia upper hand in 3rd Ashes Test
-
Asian markets mixed as US jobs data fails to boost rate cut hopes
-
Carey slams ton as Australia seize upper hand in third Ashes Test
-
Bondi shooting shocks, angers Australia Jewish community
-
Myanmar junta seeks to prosecute hundreds for election 'disruption'
-
West Indies hope Christmas comes early in must-win New Zealand Test
-
Knicks beat Spurs in NBA Cup final to end 52-year trophy drought
-
Khawaja revels in late lifeline as Australia 194-5 in 3rd Ashes Test
-
Grief and fear as Sydney's Jewish community mourns 'Bondi rabbi'
-
Trump orders blockade of 'sanctioned' Venezuela oil tankers
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
Ferreira--PC